<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618821</url>
  </required_header>
  <id_info>
    <org_study_id>FUGES-027</org_study_id>
    <nct_id>NCT05618821</nct_id>
  </id_info>
  <brief_title>Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer</brief_title>
  <official_title>Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with resectable remnant gastric cancer were selected as study subjects to&#xD;
      investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in&#xD;
      guiding laparoscopic lymph node dissection for remnant gastric cancer by comparing injection&#xD;
      ICG group and non-injection ICG group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indocyanine Green Tracer is often applied in surgery for gastric cancer. Its application in&#xD;
      laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer is at the&#xD;
      stage of cases accumulation, method studying and clinical research. There is no prospective&#xD;
      studies to identify the clinical outcomes of Indocyanine Green Tracer using in laparoscopic&#xD;
      gastrectomy with lymph node dissection for remnant gastric cancer. On the basis of more than&#xD;
      300 cases of laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer,&#xD;
      we want to apply the Indocyanine Green Tracer, a cheap, easy to operate and no radiation&#xD;
      pollution way, to predict the positive lymph nodes in remnant gastric cancer, to guid the&#xD;
      scope of laparoscopic lymph node dissection for remnant gastric cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2022</start_date>
  <completion_date type="Anticipated">April 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Retrieved Lymph Nodes</measure>
    <time_frame>30 days</time_frame>
    <description>Total Number of Retrieved Lymph Nodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lymph node noncompliance rate</measure>
    <time_frame>30 days</time_frame>
    <description>Lymph node noncompliance rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between fluorescent lymph nodes in the ICG group and total number of lymph nodes in the ICG group</measure>
    <time_frame>30 days</time_frame>
    <description>Relationship between fluorescent lymph nodes in the ICG group and total number of lymph nodes in the ICG group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between fluorescent lymph nodes in the ICG group and positive lymph nodes in the ICG group (positive rate)</measure>
    <time_frame>30 days</time_frame>
    <description>Relationship between fluorescent lymph nodes in the ICG group and positive lymph nodes in the ICG group (positive rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between fluorescent lymph nodes in the ICG group and negative lymph nodes in the ICG group (false positive rate)</measure>
    <time_frame>30 days</time_frame>
    <description>Relationship between fluorescent lymph nodes in the ICG group and negative lymph nodes in the ICG group (false positive rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between non-fluorescent lymph nodes in the ICG group and negative lymph nodes in the ICG group (negative rate)</measure>
    <time_frame>30 days</time_frame>
    <description>Relationship between non-fluorescent lymph nodes in the ICG group and negative lymph nodes in the ICG group (negative rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Metastasis Lymph Nodes</measure>
    <time_frame>30 days</time_frame>
    <description>Number of Metastasis Lymph Nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis rate of lymph node</measure>
    <time_frame>30 days</time_frame>
    <description>Metastasis rate of lymph node</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity rate</measure>
    <time_frame>30 days</time_frame>
    <description>Postoperative morbidity rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative mortality rate</measure>
    <time_frame>30 days</time_frame>
    <description>Postoperative mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>3-year overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease-free survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>3-year disease-free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year recurrence pattern</measure>
    <time_frame>3 years</time_frame>
    <description>3-year recurrence pattern</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative recovery course</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first ambulation, flatus, liquid diet and soft diet, and postoperative hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative situation</measure>
    <time_frame>30 days</time_frame>
    <description>Operation time, intraoperative blood loss, and intraoperative morbidity rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>ICG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic gastrectomy Group with the use of near-infrared imaging (ICG group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ICG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laparoscopic gastrectomy Group without the use of near-infrared imaging (Non-ICG group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine Green Tracer</intervention_name>
    <description>Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer</description>
    <arm_group_label>ICG</arm_group_label>
    <arm_group_label>Non-ICG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18 to 75 years&#xD;
&#xD;
          2. Remnant gastric cancer (cT1-4a, N-/+, M0 at preoperative evaluation according to the&#xD;
             American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition)&#xD;
&#xD;
        (4) No distant metastasis, no direct invasion of pancreas, spleen or other organs nearby in&#xD;
        the preoperative examinations (5) Performance status of 0 or 1 on the ECOG (Eastern&#xD;
        Cooperative Oncology Group) scale (6) ASA (American Society of Anesthesiology) class I to&#xD;
        III (7) Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women during pregnancy or breast-feeding&#xD;
&#xD;
          2. Severe mental disorder&#xD;
&#xD;
          3. History of previous upper abdominal surgery (except for laparoscopic cholecystectomy&#xD;
             and gastrectomy)&#xD;
&#xD;
          4. History of previous gastric surgery (including ESD/EMR for gastric cancer)&#xD;
&#xD;
          5. Rejection of laparoscopic resection&#xD;
&#xD;
          6. History of allergy to iodine agents&#xD;
&#xD;
          7. Enlarged or bulky regional lymph node diameter over 3cm by preoperative imaging&#xD;
&#xD;
          8. History of other malignant disease within past five years&#xD;
&#xD;
          9. History of previous neoadjuvant chemotherapy or radiotherapy&#xD;
&#xD;
         10. History of unstable angina or myocardial infarction within the past six months&#xD;
&#xD;
         11. History of unstable angina or myocardial infarction within past six months&#xD;
&#xD;
         12. History of continuous systematic administration of corticosteroids within one month&#xD;
&#xD;
         13. Requirement of simultaneous surgery for another disease&#xD;
&#xD;
         14. Emergency surgery due to complications (bleeding, obstruction or perforation) caused&#xD;
             by gastric cancer&#xD;
&#xD;
         15. FEV1&lt;50% of the predicted values&#xD;
&#xD;
         16. Linitis plastica, Widespread&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hualong Zheng</last_name>
    <phone>+8618359190587</phone>
    <email>291167038@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hualong Zheng</last_name>
      <phone>+8618359190587</phone>
      <email>291167038@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>June 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang, Prof.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Indocyanine Green Tracer</keyword>
  <keyword>Laparoscopic Gastrectomy</keyword>
  <keyword>Remnant Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

